Following restricted vaccine approvals and changes to CDC immunization schedules, Merck, Pfizer, GSK and Sanofi are all suffering revenue hits to their vaccine programs.
Europe's drugs regulator said on Friday it had launched a real-time review of CureVac's (5CV.DE), COVID-19 vaccine to speed ...
Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of its COVID-19 vaccine in the U.S. as Americans struggled to access the shots.
MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.
Nov 11 (Reuters) - Shortages of flu shots this year are not related to drugmakers ramping up production of potential COVID-19 vaccines, the head of vaccines at GlaxoSmithKline (GSK) (GSK.L), opens new ...
1mon
US health official calls for separating measles combination shots, pulls broad COVID vaccine support
A top U.S. health official on Monday called for the combined measles-mumps-rubella shot to be broken up, drawing a quick ...
Sometimes the biggest moments at a conference happen backstage. At the annual STAT Summit, that kind of moment involved a ...
LONDON (AP) — Drugmakers Sanofi and GlaxoSmithKline say they will seek regulatory approval for a new COVID-19 vaccine after human trials showed it provided a high level of protection against the ...
Moderna posted a smaller-than-expected quarterly loss and reduced its annual operating expenses outlook by $700 million on ...
Historically, RSV has been associated with infants, but they are not the only group that can be affected by serious RSV illness.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback